New drugs in the treatment of heart failure

Progress in Pediatric Cardiology

Volumn 12, Issue 1, 2000, Pages 119-124

  Auslender, Marcelo ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin receptor blockers; Calcium sensitizers; Developing myocardium; Pediatric pharmacology; Vesnarinone

Indexed keywords

ADENYLATE CYCLASE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM SENSITIZER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ION CHANNEL; LEVOSIMENDAN; NEUROHORMONE; NEW DRUG; PIPERANOMETOZINE; QUINOLINONE DERIVATIVE; UNCLASSIFIED DRUG;

ADULTHOOD; CELL FUNCTION; DRUG MECHANISM; ENERGY; HEART DEVELOPMENT; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE POTENTIAL; HUMAN; IMMUNOMODULATION; INOTROPISM; MORBIDITY; MORTALITY; PEDIATRICS; PRIORITY JOURNAL; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0033656606     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1058-9813(00)00063-1     Document Type: Article

References (46)

1. Determinants of angiotensin II generation during converting enzyme inhibition
2. Rationale and pharmacology of angiotensin II receptor antagonists: current statues and future issues
3. Survival in congestive heart failure during treatment with drugs with positive inotropic actions
4. A novel approach to the development of positive inotropic agents for chronic heart failure
5. Differential effects of D- and L-pimobendam cardiac myofilament calcium sensitivity
6. Mechanisms of action of calcium-sensitizing drugs
7. Effect of pimobendam on exercise capacity in patients with heart failure: main results from the Pimobendam in Congestive Heart Failure (PICO) Trial
8. Cardiac electrophysiological of levosimendan, a new calcium sensitizer
9. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation
10. Will calcium sensitizers play a role in the treatment of heart failure
11. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium
12. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men
13. Ion channel blockers in the treatment of chronic heart failure
14. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
15. Effects of phosphodiesterase inhibitors on cytokine production by microglia
16. Vesnarinone: a new inotropic agent inhibits cytokine production by stimulated human blood from patient with heart failure
17. Vesnarinone: a potential cytokine inhibitor
18. The integrated effects of angiotensin II
19. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials
20. Determinants of angiotensinn II generation during converting enzyme inhibition
21. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology
22. Bradykinin modulation of isolated rabbit heart function is mediated by intrinsic cardiac neurons
23. Bradykinin B2-receptor activation augments norepinephrine exocytosis from cardiac sympathetic endings. Mediation by autocrine/paracrine mechanisms
24. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type I antagonists
25. Angiotensin II-forming pathways in normal and failing hearts
26. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart
27. Alternative pathways of angiotensin II production in the human saphenous vein
28. 'Escape' of aldosterone production in patients with left ventricular dysfunction treated with angiotensin converting enzyme inhibitor: implications for therapy
29. Recent insight into the therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism
30. Expression of AT2 receptors in the developing rat fetus
31. Differential distribution of angiotensin AT2 receptors in the normal and the failing heart
32. Physiological and pharmacological implications of AT1 versus AT2 receptors
33. Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts
34. AT2 receptor blockade reduced cardiac interstitial cell DNA synthesis and cardiac function after rat myocardial infarction
35. Angiotensin II type II receptor mediates programmed cell death
36. Angiotensin induction of PAI-1expression in endothelial cells is mediated by the hexapeptide angiotensin IV
37. Coagulation factor abnormalities after the Fontan procedure and its modifications
38. Randomized trial of losartan versus captopril in patients over 65 with heart failure
39. Comparison of cabdesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. The RESOLVD Pilot Study Investigators
40. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure
41. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure
42. Enalapril for severe heart failure in infancy
43. Short-term hemodynamic effects of captopril in infants with congestive heart failure
44. Captopril in children with dilated cardiomyopathy: acute and long-term effects in prospective study of hemodynamic and hormonal effects
45. Angioedema induced by the angiotensin II blocker losartan
46. Angioedema due to losartan